COMMUNIQUÉS West-GlobeNewswire

American Journal of Psychiatry Publishes Minerva Neurosciences' MIN-101 Phase 2b Trial Results for Treatment of Negative Symptoms in Schizophrenia
31/07/2017
WALTHAM, Mass., July 31, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, [...]
Medtronic Announces CE Mark and European Launch of CoreValve(TM) Evolut(TM) PRO Transcatheter Valve with Advanced Sealing
31/07/2017
DUBLIN - July 31, 2017 - Medtronic plc (NYSE:MDT) today announced CE (Conformité Européenne) mark and European launch of the CoreValve(TM)Evolut(TM) PRO valve for the treatment of severe aortic stenosis for symptomatic [...]
RedHill Biopharma Announces Unanimous Positive DSMB Recommendation for Continuation of the Phase III Study with RHB-104 for Crohn's Disease
31/07/2017
The independent Data and Safety Monitoring Board (DSMB) reviewed safety and efficacy data, of which RedHill remains blinded, from the first 222 subjects who have completed week 26 assessments in the Phase III MAP US [...]
EDAP Announces filing of 510(k) Application for Ablatherm-Fusion® device
31/07/2017
LYON, France, July 31, 2017 -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that the Company submitted a 510(k) application for its Ablatherm Fusion device, enabling a more [...]
Spark Therapeutics Submits Marketing Authorization Application to European Medicines Agency for Investigational LUXTURNA(TM) (voretigene neparvovec)
31/07/2017
Potential for first gene therapy for a genetic disease to be approved in both the U.S. and EU PHILADELPHIA, July 31, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company [...]
ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders
31/07/2017
ProMIS' shareholders show overwhelming support for all resolutions TORONTO and CAMBRIDGE, Mass., July 31, 2017 - ProMIS Neurosciences, Inc. (the "Company"), a biotechnology company focused on the discovery and [...]
uniQure Reacquires Development and Commercialization Rights for its Gene Therapy Candidate in Hemophilia B
31/07/2017
~ Company now owns full global rights to late-stage program with clinical proof-of-concept ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, July 31, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene [...]
Arix Bioscience Half Yearly Report for the Six Months Ended 30 June 2017
31/07/2017
Arix Bioscience Half Yearly Report for the Six Months Ended 30 June 2017 Transformative period with good progress across the business LONDON, 31 July 2017: Arix Bioscience plc (LSE:ARIX) ("Arix Bioscience", "Arix" or [...]
Passing of Zealand Pharma A/S Extraordinary General Meeting on 31 July 2017
31/07/2017
Company announcement - No. 28/ 2017 Passing of Zealand Pharma A/S Extraordinary General Meeting on 31 July 2017 Copenhagen, 31 July 2017 - Today, Zealand Pharma A/S (Zealand) (CVR-no. 20 04 50 78) held an extraordinary [...]
Kymab Announces Clinical Update on its promising new antibody KY1005 for treatment of autoimmune diseases
31/07/2017
Kymab Announces Clinical Update on its promising new antibody KY1005 for treatment of autoimmune diseases The third dosing cohort has been completed and 24 patients have now been dosed . KY1005-CT01 clinical study is [...]
FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares
31/07/2017
FIT Biotech Oy Company release July 31, 2017 at 10:00 AM EET Conversion of FIT Biotech Oy's Convertible Capital Notes into shares Related to Convertible Note and Warrant Programmes established on September 26, 2016 [...]
Zealand reports royalty revenue for the second quarter of 2017
31/07/2017
Company announcement - No. 27/2017 Zealand reports royalty revenue for the second quarter of 2017 Zealand reports royalty revenue of DKK 9.1 million in Q2 2017 The revenue is based on total net sales of of Lyxumia ® / [...]
NICOX : Assemblée Générale Ordinaire le 21 août 2017
31/07/2017
Communiqué de presse Assemblée Générale Ordinaire le 21 août 2017 Modalités de mise à disposition des documents préparatoires 31 juillet 2017 - diffusion à 7h30 Sophia Antipolis, France Les actionnaires de la société [...]
NICOX : Ordinary Shareholder meeting of August 21, 2017
31/07/2017
Press Release Ordinary Shareholder meeting of August 21, 2017 Conditions of availability of the preparatory documents July 31, 2017 - release at 7:30 am CET Sophia Antipolis, France The shareholders of Nicox are [...]
Sanofi Raises FY 2017 Business EPS(1) Guidance to Broadly Stable at CER(2)
31/07/2017
Paris, July 31, 2017 Sanofi Raises FY 2017 Business EPS (1) Guidance to Broadly Stable at CER (2) Q2 2017 Change Change at CER Change at CER/CS (3) H1 2017 Change Change at CER Change at CER/CS (3) IFRS net sales [...]
Sanofi relève ses perspectives de BNPA des activités(1) 2017 à globalement stable à TCC(2)
31/07/2017
Paris, le 31 juillet 2017 Sanofi relève ses perspectives de BNPA des activités (1) 2017 à globalement stable à TCC (2) T2 2017 Var. Var. à TCC Var. à TCC et PC (3) S1 2017 Var. Variation à TCC Var. à TCC et PC (3) [...]
NEOVACS : LÈVE AVEC SUCCÈS 6 M€ PAR PLACEMENT PRIVE AUPRÈS D'INVESTISSEURS INSTITUTIONNELS EN BIOTECHNOLOGIE AMERICAINS
31/07/2017
COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE NEOVACS LÈVE AVEC SUCCÈS 6 M€ PAR PLACEMENT PRIVE AUPRÈS D'INVESTISSEURS INSTITUTIONNELS EN BIOTECHNOLOGIE AMERICAINS Paris et Boston , le 31 juillet [...]
NEOVACS : SUCCESSFULLY RAISES €6.0 MILLION IN PRIVATE PLACEMENT WITH U.S. BIOTECHNOLOGY INSTITUTIONAL INVESTORS
31/07/2017
PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS SUCCESSFULLY RAISES € 6.0 MILLION IN PRIVATE PLACEMENT WITH U.S. BIOTECHNOLOGY INSTITUTIONAL INVESTORS Paris and Boston, July 31, 2017 - 7:30 am CET - Neovacs ( [...]
La cour d'appel des États Unis pour le circuit fédéral confirme la plainte de Merus pour conduite inéquitable contre Regeneron
31/07/2017
UTRECHT, Pays-Bas, le 31 juillet 2017 (GLOBE NEWSWIRE) - Merus N.V. (Nasdaq : MRUS), société d'immuno-oncologie de stade clinique qui développe des traitements innovants à base d'anticorps bispécifiques (Biclonics ® ), [...]

Pages